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Medina-Gomez G, Calvo RM, Obregon M-J. Thermogenic ef-
fect of triiodothyroacetic acid at low doses in rat adipose tissue
without adverse side effects in the thyroid axis. Am J Physiol Endo-
crinol Metab 294: E688–E697, 2008. First published February 19,
2008; doi:10.1152/ajpendo.00417.2007.—Triiodothyroacetic acid
(TRIAC) is a physiological product of triiodothyronine (T3) metabo-
lism, with high affinity for T3 nuclear receptors. Its interest stems
from its potential thermogenic effects. Thus this work aimed 1) to
clarify these thermogenic effects mediated by TRIAC vs. T3 in vivo
and 2) to determine whether they occurred predominantly in adipose
tissues. To examine this, control rats were infused with equimolar T3
or TRIAC doses (0.8 or 4 nmol 100 g body wt1 day1) or exposed
for 48 h to cold. Both T3 doses and only the highest TRIAC dose
inhibited plasma and pituitary thyroid-stimulating hormone (TSH)
and thyroxine (T4) in plasma and tissues. Interestingly, the lower
TRIAC dose marginally inhibited plasma T4. T3 infusion increased
plasma and tissue T3 in a tissue-specific manner. The highest TRIAC
dose increased TRIAC concentrations in plasma and tissues, decreas-
ing plasma T3. TRIAC concentrations in tissues were 10% those of
T3. Under cold exposure or high T3 doses, TRIAC increased only in
white adipose tissue (WAT). Remarkably, only the lower TRIAC dose
activated thermogenesis, inducing ectopic uncoupling protein (UCP)-1
expression in WAT and maximal increases in UCP-1, UCP-2, and
lipoprotein lipase (LPL) expression in brown adipose tissue (BAT),
inhibiting UCP-2 in muscle and LPL in WAT. TRIAC, T3, and cold
exposure inhibited leptin secretion and mRNA in WAT. In summary,
TRIAC, at low doses, induces thermogenic effects in adipose tissues
without concomitant inhibition of TSH or hypothyroxinemia, suggest-
ing a specific role regulating energy balance. This selective effect of
TRIAC in adipose tissues might be considered a potential tool to
increase energy metabolism.
thermogenesis; leptin; lipoprotein lipase; deiodinases
THE MAIN PATHWAYS of triiodothyronine (T3) metabolism are
deiodination, conjugation with glucuronides and sulfates, and
modification of the alanine chain producing acetic and propi-
onic metabolites. Triiodothyroacetic acid (TRIAC, also known
as Tiratricol) is a physiological product of T3 metabolism,
derived by deamination and oxidative decarboxylation of the
alanine chain (55). In humans, TRIAC production by the liver
and other tissues accounts for 14% of T3 metabolism (17).
This production is increased under certain physiological con-
ditions, such as fasting (29). Serum TRIAC concentrations in
humans are very low (42–140 pM) (17, 35, 38). The free
fraction in serum is lower than that of T3, due to higher binding
to plasma proteins, especially to transthyretin (18, 35). TRIAC
has a faster metabolic clearance rate and shorter half-life than
T3 in humans (35), due to its rapid hepatic metabolism, via the
formation of sulfates and glucuronides, especially in humans
(36, 51).
TRIAC has a higher affinity than T3 for thyroid hormone
nuclear receptors (TR), especially the 1-isoform of the nu-
clear TR (TR-1), in various cell types (52) and also in rat
brown adipocytes (20). In pituitary cells “in vitro,” TRIAC
elicits a similar response to T3, inhibiting thyroid-stimulating
hormone (TSH) secretion (16). In fact, TRIAC has been used
to suppress TSH secretion in patients with thyroid hormone
resistance, inappropriate TSH secretion, or thyroid carcinoma
(2, 23, 60) because it exerts fewer effects on cardiac function
than T3. However, due to its rapid metabolism in humans, high
daily doses are required (0.4 to 1–2 mg TRIAC), 200 times
higher than physiological doses of T3. At these high doses,
TRIAC induces persistent hypothyroidism due to TSH suppres-
sion. Other thyromimetic actions of TRIAC include decreases in
cholesterol or lipids and an increase in the expression of several
T3-dependent genes [sex hormone-binding globulin (SHBG),
Spot 14 (S14), type I 5-deiodinase (D1)] (9, 22, 26, 53, 54) in
liver, a tissue with predominant TR-1 expression.
A specific role, different from that of T3, has not been
ascribed to TRIAC. Previous attempts to demonstrate TRIAC
effects promoting oxygen consumption or energy expenditure
have been inconclusive. Whereas some early experiments re-
ported that TRIAC increased oxygen consumption (47) and
suggested a possible role regulating energy expenditure (13),
other studies failed to do so (3, 27), despite the fact of evidence
of thyromimetic actions on lipids (9, 23, 53). Brown adipose
tissue (BAT) is specialized in the production of heat in facul-
tative thermogenesis. This function is mediated by uncoupling
protein (UCP)-1 (39). Cold exposure and cafeteria diets are
typical experimental paradigms used to stimulate BAT activity
and UCP-1 expression via the release of norepinephrine (NE)
from sympathetic nerve endings. BAT activity is an important
determinant of energy balance (61). Thyroid hormones are
essential for basal and facultative thermogenesis, in particular
for the full expression of UCP-1 (5, 58). UCP-1 expression and
its response to cold are low in hypothyroid adult rats, fetuses,
and newborns (6, 43). Thyroid hormone administration restores
UCP-1 mRNA levels and its response to cold (6, 41). T3
increases the transcription rate, stabilizes UCP-1 mRNA tran-
scripts, and increases the effect of NE (4, 5, 48). T3 concen-
trations in BAT are elevated, especially under cold exposure
and during fetal life (44, 57). T3 in BAT is produced by type II
5-deiodinase (D2), which is activated in response to cold (56).
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This T3 production is required for the high saturation of nuclear
T3 receptors in response to cold exposure and for optimal
thermogenic function (57).
Our previous studies using brown adipocytes have shown
that TRIAC at very low concentrations (0.2 nM) had more
thermogenic effect than T3 (34), increasing the adrenergic
stimulation of both UCP-1 mRNA and D2 activities. Therefore
we hypothesized that TRIAC could also be a thermogenic
agent in vivo that might increase energy expenditure and
regulate T3 production (by increasing D2) in BAT. The objec-
tive of the present study was to characterize the specific effects
of TRIAC in vivo and to compare them with those of T3,
especially in adipose tissue. Of particular interest was to define
the therapeutic potential of TRIAC metabolic effects at low
doses. Our results show that TRIAC at low doses is able to
induce ectopic UCP-1 in white adipose tissue (WAT), that
TRIAC is effective in leading to multiple changes in thermo-
genic and lipid-related gene expression in adipose tissues, and
that these changes are not found in all the tissues with pre-
dominant TR-1 expression (i.e., liver).
MATERIALS AND METHODS
Materials. Thyroxine (T4), T3, 3,5-diiodothyronine, DTT, 6-n-
propyl-2-thiouracil (PTU), MOPS, and agarose were obtained from
Sigma (St. Louis, MO). TRIAC, diiodothyroacetic acid (DIAC),
reverse T3 (rT3) and 3,3-diiodothyronine were obtained from Hen-
ning Berlin (Berlin, Germany). 125I, 131I, and [-32P]dCTP were
obtained from Amersham International (Aylesbury, UK). The oligo-
labeling system was from Pharmacia (Uppsala, Sweden). Nytran
membranes were from Schleicher & Schuell (Dassel, Germany). All
other chemicals were molecular biology grade.
Experimental design. Female Sprague-Dawley rats were used.
They were housed under humane conditions, under veterinary control,
according to the European Community guidelines and after approval
by the Ethics Committee of our institution. The rats were maintained
at 22°C with 12-h periods of light and darkness and were fed a stock
pellet diet (Sandermus; Sanders, Barcelona, Spain). The rats (243 
3 g body wt, n  5/group) were implanted with osmotic minipumps
(2ML 2; Alza, Palo Alto, CA) under the dorsal skin that delivered two
equimolar doses of T3 or TRIAC (0.8 or 4 nmol 100 g body
wt1 day1, which correspond to 0.52 and 2.6 	g T3 and 0.5 and
2.49 	g TRIAC 100 g body wt1 day1). The doses were chosen
following previous experiments done infusing increasing doses of T3
(14, 15) on the basis of the T3 concentrations found in several tissues
using low and high T3 doses. After 12 days of continuous infusion, the
animals were killed. After being bled, several tissues were obtained
and quickly frozen on dry ice. Skeletal muscle was obtained from the
hind leg and WAT from the abdominal depots, excluding perirenal
depots. One group of control rats was infused with placebo, and
another group was maintained in individual cages in a cold room at
8°C for 48 h. The T3 and TRIAC doses for infusion were dissolved
using 0.05 N NaOH and were diluted in saline 
 2% BSA.
RIAs of T4, T3, and TRIAC in plasma and tissues. Thyroid hormone
concentrations were determined by RIA after extraction and purifica-
tion of plasma and tissues as previously described (37) by using
methanol-chloroform extraction, back extraction into an aqueous
phase, and purification of plasma and tissue extracts on DOWEX 1X2
columns. This procedure retains TRIAC in the DOWEX, avoiding any
interference of TRIAC in the T3 RIA. Thyroid hormones were
determined in the purified extracts by using sensitive RIAs (37). The
cross-reactivity and sensitivity of the RIAs were described (50).
Samples were processed in duplicate at two dilutions. The final results
were calculated by using individual recovery data obtained by the
addition of tracer amounts of [131I]T4 and [125I]T3 to the initial
homogenates.
TRIAC concentrations were determined in extracts from plasma
and tissues by specific RIA, using a specific TRIAC antibody (kindly
provided by Dr. A. Burger). Plasma and tissue homogenates were
used, and 2,000 cpm of [125I]TRIAC were added to each tube to
calculate individual recoveries, extracted with methanol, and filtered
through Microsep microconcentrators (3K filters; Filtron Technology,
Pall, NY). The purified extracts were evaporated to dryness and were
reconstituted with RIA buffer. The standard curve was done in buffer
(0.04 M phosphate, pH 8, 0.2% BSA, and 0.6 mM merthiolate) and
ranged from 0.9 to 250 pg TRIAC/tube, with a detection limit of 0.9
pg TRIAC/tube. Cross-reactivity with T3 was 0.16%.
TSH, growth hormone, and leptin RIAs. TSH was determined in 50
	l of plasma by using the reactives for rat TSH RIA, kindly supplied
by the National Institutes of Health (Bethesda, MD), and were made
available through the Rat Pituitary Agency of the National Institute of
Diabetes, Digestive, and Kidney Diseases (NIDDK). Concentrations
are expressed in weight equivalents of the NIDDK-rTSH-RP-3 refer-
ence preparation. [125I]TSH was labeled by using lactoperoxidase.
Hyperthyroid rat serum was used to set up the standard curve to
improve the sensitivity of the TSH RIA (0.06 ng/ml plasma). TSH and
growth hormone (GH) were also determined in pituitary glands by
using standard curves in buffer. One-fiftieth of the pituitary was
further diluted 1:100 for TSH and 1:10.000 for GH. Leptin concen-
trations were measured by using a sensitive and specific rat leptin RIA
kit from Linco Research (St. Charles, MO). The intra- and intercoef-
ficients of variation for this assay were 4.0% and 11.2%, respectively.
Radioactive products. High-specific-activity [131I]T4, [125I]T4,
[125I]T3, [125I]rT3, and [125I]TRIAC (3,000 	Ci/	g) were synthesized
in our laboratory from the substrate with a lower degree of iodination
and were used for the highly sensitive T4, T3, and TRIAC RIAs; as
recovery tracers for extraction; and as substrates for D1 and D2.
Iodothyronine 5-deiodinase (D1 and D2) activities. Before each
assay, [125I]rT3 or [125I]T4 was purified by paper electrophoresis to
separate the iodide. Iodothyronine 5-deiodinase activities were as-
sayed as described (44, 50). The experimental conditions for D1 in
liver and kidney were 400 nM rT3 ([125I]rT3) 1 mM PTU and 2 mM
DTT for 10 min (30 	g protein) and for D1 in heart and pituitary were
2 nM rT3 ([125I]rT3)  1 mM PTU and 20 mM DTT for 1 h. For D2
activity in BAT and pituitary, conditions were 2 nM T4 ([125I]T4) 

1 	M T3 and 20 mM DTT in the presence of 1 mM PTU for 1 h
(150–200 	g protein). All incubations were done at 37°C. The 125I
released was separated by ion-exchange chromatography on DOWEX
50W-X2 columns equilibrated in 10% acetic acid. The protein content
was determined by the method of Lowry et al. (30), after precipitation
of the homogenates with 10% TCA to avoid interferences from DTT
in the colorimetric reaction.
RNA preparation and Northern blot analysis. Total RNA was
extracted by using Trizol (GIBCO-BRL Life Technologies, Grand
Island, NY). Total RNA (15 	g) was denatured and electrophoresed
on a 2.2 M formaldehyde-1% agarose gel in 1MOPS buffer and was
transferred to nylon membranes. Several genes were analyzed: UCP-1
(8), UCP-2 and leptin (33), UCP-3, lipoprotein lipase (LPL) and -
and -myosin heavy chain (MHC), and hyperpolarization-activated
cyclic nucleotide-gated channel 2 (HCN2) (46). The cDNAs were
used as templates for [-32P]dCTP-labeled probes by using random
primers (108 cpm/	g DNA). Filters were hybridized and washed
under standard conditions. Alternatively for leptin and UCP-3,
ULTRAHyb (Ambion, Huntingdon, UK) was used. Autoradiograms
were obtained from the filters and were quantified by laser computer-
assisted densitometry (Molecular Dynamics, Sunnyvale, CA) or NIH
Image software. The membranes were routinely dyed with methylene
blue to visualize the ribosomal RNAs, and differences between lanes
were used to correct the results obtained (cyclophilin expression was
very low in some tissues such as muscle and WAT). Results are
expressed as means  SE of two to four determinations.
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Statistical analysis. Mean values  SE are given. When not visible
in the figures, SE was smaller than the size of the symbols. One-way
analysis of variance was applied after ensuring homogeneity of
variance by Bartlett’s test. Statistically significant differences between
mean values of different groups were then identified by the least
significant difference method. All calculations were performed as
described by Snedecor and Cochran (59).
RESULTS
Low doses of TRIAC inhibit less plasma T4 and TSH than T3.
As expected, T3 and TRIAC inhibited plasma T4. However, at
equimolar doses the infusion of T3 had more effect than
TRIAC at inhibiting T4 (10% of control values for both T3
doses; Fig. 1), whereas the effect of TRIAC was smaller (70%
and 40% of control values for the low and high TRIAC doses).
At the lowest dose, TRIAC did not affect plasma TSH,
whereas both doses of T3 and the highest dose of TRIAC
markedly reduced TSH levels. Pituitary TSH content mim-
icked the pattern observed in plasma TSH, suggesting that
changes in plasma TSH were secondary to changes in pituitary
TSH. The low TSH stimulation led to low T4 thyroidal secre-
tion. Pituitary GH did not change under T3 or TRIAC infusion.
Furthermore, the infusion of T3 and TRIAC to control rats
increased their respective plasma concentrations in proportion
to the doses infused, and the increases were higher for TRIAC
than for T3 (1.5- and 3.6-fold increases in plasma T3 for both
T3 doses and 4.5- and 18-fold increases in plasma TRIAC for
both TRIAC doses). This could be related to the higher binding
of TRIAC to plasma proteins. T3 concentrations in plasma
decreased by 50% by infusion of the highest TRIAC dose,
whereas none of the T3 doses increased plasma TRIAC con-
centrations. Cold exposure for 48 h did not alter plasma T4 or
TRIAC but increased plasma T3 and TSH, with no changes in
pituitary TSH.
Low doses of TRIAC do not affect T4 and T3 concentrations
in rat tissues. T4 and T3 concentrations were measured in BAT,
WAT, heart, skeletal muscle, liver, and kidney (Fig. 2). T4
concentrations (top panels) were decreased in all tissues by
both T3 doses; however, the decreases observed were less
pronounced than the changes seen in plasma T4. Conversely,
the lowest TRIAC dose did not inhibit T4 in tissues, whereas
the highest TRIAC dose resulted in a smaller inhibitory effect
(50% of control, except for BAT T4).
With respect to T3 concentrations, they changed heteroge-
neously among the tissues studied (Fig. 2, bottom panels). For
instance, T3 infusion led to minimal increases in BAT T3
levels, suggesting that circulating T3 is probably less relevant
than locally produced T3 in BAT. In WAT, only the highest
dose of T3 induced a threefold increase in WAT T3. In heart
and muscle, the infusion of both T3 doses resulted in similar
increases (two- and fourfold increases). Finally, in liver and
kidney only the high T3 dose led to clear increases (four- and
sixfold, respectively). Cold exposure increased BAT T3 and T4,
T3 in heart and muscle, and liver T4. Of interest, only the
highest dose of TRIAC reduced T3 by 50% in heart, liver, and
kidney, parallel to levels of T3 in plasma. Therefore the effects
observed in the TRIAC-infused rats could be attributed to
TRIAC, because T3 did not increase after TRIAC infusion.
Together, these data indicate that low doses of TRIAC do
not decrease T4 concentrations in tissues, similarly to what
happened in plasma.
Concentrations of TRIAC in different rat tissues. TRIAC
concentrations were 10–20% of T3 concentrations in each
tissue studied. The highest concentration of TRIAC was found
in BAT, followed by heart  WAT  muscle  kidney 
liver (range: 0.07–0.4 ng/g tissue, 0.12–0.64 nM).
Infusion of TRIAC at the highest dose increased TRIAC
concentrations in BAT (Fig. 3). TRIAC concentrations in
WAT only reached 50% of BAT (Fig. 3) and increased less
with 4 nmol of TRIAC than in BAT. Interestingly, the highest
T3 dose and cold exposure increased TRIAC concentrations by
twofold in WAT, suggesting T3 as the main source of TRIAC
in both situations, a finding only observed in WAT. In heart,
TRIAC concentrations, although higher, followed a similar
pattern to those in BAT. The lowest TRIAC concentrations
Fig. 1. Plasma thyroid-stimulating hormone
(TSH), thyroxine (T4), triiodothyroxine (T3),
and triiodothyroacetic acid (TRIAC) concen-
trations and TSH and growth hormone (GH)
pituitary contents. Control rats (C) were in-
fused with 0.8 or 4 nmol of TRIAC or T3  100
g body wt1  day1 for 12 days or were
exposed to cold for 48 h (Cold). Plasma T4,
T3, TSH, and TRIAC concentrations and
TSH and GH pituitary contents are shown
(means  SE). *P  0.05 vs C.
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were found in muscle, kidney, and liver. Finally, the largest
increases of TRIAC were found in liver (12- and 45-fold for
both TRIAC doses). In kidney, the increases were similar to
plasma and heart.
The tissue-to-plasma ratios for TRIAC were1 in BAT and
heart and lower in the rest of the tissues (0.3–0.6) and were
always lower than T3 tissue-to-plasma ratios (1 in all tissues,
10–20 in BAT).
Induction of ectopic UCP-1 in WAT by the lowest dose of
TRIAC. We hypothesized that TRIAC could be a thermogenic
agent, so we investigated whether TRIAC could upregulate the
expression of UCP-1 in BAT. As expected, cold exposure
increased UCP-1 mRNA in BAT (Fig. 4). The lowest TRIAC
dose induced UCP-1 expression in BAT more effectively than
either T3 dose or the highest TRIAC dose. Interestingly, and
unexpectedly, the lowest TRIAC dose (0.8 nmol) induced
ectopic expression of UCP-1 in abdominal WAT (3 different
rats). This effect was not observed with either the highest
TRIAC dose, both doses of T3, or even under cold exposure.
These effects on UCP-1 expression were associated with TRIAC
concentrations in BAT of10% those of T3 (1 nM TRIAC vs. 10
nM T3), and only 0.3 nM TRIAC was found in WAT after the
infusion of the lowest TRIAC dose (Figs. 2 and 3). Therefore,
these actions of TRIAC in WAT were exerted at very low
Fig. 2. T4 and T3 concentrations found in brown adipose tissue (BAT), white adipose tissue (WAT), heart, skeletal muscle, liver, and kidney. T4 and T3 were
determined by RIAs in purified tissue extracts. Experimental groups are same as described in Fig. 1 (means  SE). *P  0.05 vs. C, #P  0.05 vs. Cold, &P 
0.05 vs. 0.8 nmol TRIAC, ¶P  0.05 vs. 4 nmol TRIAC, §P  0.05 vs. 0.8 nmol T3, and P  0.05 vs. 4 nmol T3.
Fig. 3. TRIAC concentrations found in BAT,
WAT, heart, skeletal muscle, liver, and kid-
ney. TRIAC was determined by RIA in puri-
fied tissue extracts. Experimental groups are
same as described in Fig. 1 (means  SE).
*P  0.05 vs. C, #P  0.05 vs. Cold, &P 
0.05 vs. 0.8 nmol TRIAC, ¶P  0.05 vs. 4
nmol TRIAC, §P  0.05 vs. 0.8 nmol T3, and
P  0.05 vs. 4 nmol T3.
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concentrations compared with T3 and with no change in T3
concentrations. D2 expression was also measured in WAT, and
it was not induced by the low TRIAC dose (results not shown).
The expression of UCP-2 and UCP-3 in different tissues was
also examined. In BAT, UCP-2 mRNA showed the greatest
increase in response to the lower dose of TRIAC, cold expo-
sure, and both doses of T3. The highest TRIAC dose had no
effect (Fig. 5). In WAT, UCP-2 mRNA was only increased by
the lowest dose of T3. In muscle, T3 and TRIAC had an
inhibitory effect on UCP-2 mRNA, with the lowest TRIAC
dose, the highest T3 dose, and cold exposure being more
effective. In heart, UCP-2 mRNA expression was higher than
in other tissues, and both doses of T3 and TRIAC induced
UCP-2 with similar effect. Cold exposure induced UCP-2
mRNA fourfold. Therefore the regulation of UCP-2 is tissue
specific, and the lowest TRIAC dose has a similar effect to the
highest T3 dose only in BAT and muscle.
The expression of UCP-3 mRNA was only detectable in BAT
and muscle. The highest T3 dose and cold exposure had a
maximal effect in BAT and muscle UCP-3. There was no effect
using both TRIAC doses and the lowest T3 dose, in contrast to the
findings for UCP-1 and UCP-2. Some induction of UCP-3 was
observed in WAT by using the highest T3 dose and the lowest
TRIAC dose (not shown), but UCP-3 could not be quantified.
Expression of LPL in BAT, WAT, and heart. LPL recruits the
lipids necessary for mitochondrial combustion in BAT, and
Fig. 4. Uncoupling protein (UCP)-1 mRNA expres-
sion in BAT and WAT. Total RNA was extracted
from BAT and WAT of rats from experimental
groups described in Fig. 1. Hybridization with UCP-1,
rRNA staining, and UCP-1/rRNA ratio are shown
(means  SE, n  2–3). Results for WAT were re-
peated with 3 different rats/group. *P  0.05 vs. C.
Fig. 5. UCP-2 and UCP-3 mRNA expression
in BAT, WAT, heart, and muscle. Total RNA
was extracted from BAT, WAT, heart, and
skeletal muscle of rats from experimental
groups described in Fig. 1. Hybridization with
UCP-2 and UCP-3, rRNA staining, and
UCP-2 or UCP-3/rRNA ratio are shown
(means  SE, n  2). *P  0.05 vs. C.
E692 TRIAC ACTIONS IN RATS
AJP-Endocrinol Metab • VOL 294 • APRIL 2008 • www.ajpendo.org
cold exposure increases LPL activity in BAT (10). In BAT,
LPL mRNA was induced by the lowest T3 and TRIAC doses
(Fig. 6) and was inhibited by the highest T3 dose, similarly to
our previous findings in cultured brown adipocytes (34). An
inhibitory pattern in LPL expression was observed in WAT,
with maximum inhibition observed following the highest T3
dose, the lowest TRIAC dose, and after cold exposure. These
findings indicate new aspects in the dose-dependent responses
of LPL in BAT and WAT. Again, the lowest TRIAC dose and
the highest T3 dose had a similar effect, pointing to a higher
effect of TRIAC. LPL has been studied in heart previously (7,
40). TRIAC had no effect on LPL in heart, and only cold
exposure and the highest T3 dose inhibited LPL in heart,
similar to the findings in WAT.
Leptin secretion and mRNA levels are inhibited by TRIAC
and T3. In our previous studies (33), we showed that leptin
secretion and mRNA were inhibited by T3 and TRIAC in white
and brown adipocytes. In this study, we found that plasma
leptin was inhibited by T3, TRIAC, and cold exposure (Fig. 7)
and that the highest T3 dose had a maximal effect. Leptin
mRNA was also inhibited in WAT, but the maximal effect was
observed with the highest TRIAC dose and cold exposure.
Again, the highest T3 dose and the lowest TRIAC dose had a
similar effect. In BAT, leptin mRNA expression was too low to
be quantified (not shown).
Effect of TRIAC and T3 on D1 and D2. The deiodinases are
the main source of T3 in tissues and are regulated by T3. We
examined the responses of D1 and D2 in tissues with different
levels of TR-1 or TR-1 isoforms. Liver and kidney D1
activities increased with the high doses of T3 and TRIAC (Fig. 8).
Maximal increases were obtained with the highest T3 dose,
TRIAC being less effective in the induction of D1 activity. In
heart, only the highest T3 dose increased D1 activity, whereas
none of the TRIAC doses had an effect, despite the very high
TRIAC concentrations reached in heart. Cold exposure did not
affect D1 activity in the former tissues. Similar results (higher
T3 effect) were found for D1 mRNA in liver and kidney
(results not shown).
In BAT, D2 accounts for the local production of T3. BAT D2
activity was suppressed by the lowest TRIAC dose (35% of
control) and increased with the highest T3 dose (5-fold) and
cold exposure (8-fold). Pituitary D2 increased twofold with
the highest T3 dose. Pituitary D1 (86% of the total activity) did
not change with any of the treatments (not shown). D2 in
cerebral cortex was induced by both T3 doses and by the
highest TRIAC dose.
Similar effect of TRIAC and T3 in heart. It has been shown
that TRIAC has a lesser effect on the heart than T3 (27, 53). For
this reason, the expression of three genes (- and -MHC and
HCN2) regulated in heart by T3 was investigated (Fig. 9).
Both, - and -MHC have been shown as regulated in opposite
directions by hypothyroidism, with -MHC levels decreasing
and -MHC levels increasing. These opposite changes are not
always found after treatment with T3 (46, 62). In our model, an
inhibition of -MHC was observed in a dose-dependent man-
ner when using T3 and TRIAC and by cold exposure. No
difference was observed between T3 and TRIAC. The effects
on -MHC are less intense, and an inhibition was only ob-
served under cold exposure. The expression of HCN2 in-
creased only after the high T3 dose. LPL mRNA in heart was
inhibited only by the highest T3 dose and cold exposure (Fig.
6). In heart, T3 concentrations were fourfold those of TRIAC.
Unexpectedly, after infusion of 4 nmol TRIAC, the concentra-
tions of TRIAC in heart were the highest of any of the tissues
studied, similar to those of liver; despite this, the effects of
TRIAC and T3 were similar in heart.
DISCUSSION
TRIAC is a physiological product of T3 metabolism, with
high affinity for the TR-1 isoform. Its biological functions are
assumed to be similar to those of T3, but it is not known
whether TRIAC has specific but as yet unidentified roles. The
present study provides evidence of specific effects of TRIAC
different from those of T3, especially in adipose tissue, in a
model that does not use TRIAC as substitution therapy, be-
cause it is known that T4 is required for the production of T3.
One of the best-characterized effects of TRIAC is the inhibi-
tion of TSH levels (3, 9, 16) accompanied in humans by low T4
levels and persistent hypothyroidism. In our study, the infusion
of both T3 doses and the high TRIAC dose decreased T4
concentrations in plasma and tissues and inhibited pituitary
TSH and the thyroidal synthesis of T4. However, the lowest
dose of TRIAC had no effect on plasma TSH, although it
Fig. 6. Expression of lipoprotein lipase (LPL) in BAT, WAT,
and heart. Total RNA was extracted from BAT, WAT, and
heart of rats from groups described in Fig. 1. Hybridization
with LPL, rRNA staining, and LPL/rRNA ratio are shown
(means  SE, n  2–3). *P  0.05 vs. C.
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decreased plasma T4 slightly, suggesting an effect of TRIAC
on pituitary TSH, which did not affect T4 concentrations in
tissues. Therefore, TRIAC infusion seems less effective than
T3 infusion in inhibiting TSH, which is opposite to the findings
in pituitary cells (16), probably due to a lower effect of TRIAC
or lower TRIAC concentrations in the pituitary. Decreased
plasma TSH follows the pattern of changes in pituitary TSH.
This was already observed in hyperthyroid rats (42), in which
the lack of response of TSH to thyrotropin-relasing hormone
(TRH) was due to the complete depletion of pituitary TSH and
not to high T3 concentrations in the pituitary. The cold-exposed
group is an exception to the parallel changes found in plasma
and pituitary TSH. Whereas T3 infusion caused a profound
inhibition of TSH synthesis and secretion and possibly that of
TRH, the adrenergic stimulation under cold exposure increased
TRH secretion, leading to increases in TSH and plasma T3 (and
BAT T3). Thus the stimulation of TRH overcame the inhibition
by T3. The low serum T4 was followed by low T4 in tissues in
all the rats infused with T3 and the highest TRIAC dose, but not
in those on the lowest TRIAC dose. Although the decrease in
T4 in the tissues was less pronounced than in plasma, the
tissue/plasma T4 ratios were higher in the rats infused with
both T3 doses than in those infused with TRIAC. These data
indicate that there is increased T4 uptake to avoid tissue
hypothyroxinemia.
The infusion of T3 led to highly variable T3 increases in the
different tissues depending on the contribution of plasma-
derived (liver, kidney) or locally produced T3 (BAT).TRIAC
concentrations have been reported in plasma (17, 35, 38), but
our study presents the first data on TRIAC concentrations in rat
tissues, which were always lower than those of T3 (10%).
Except for decreases in heart, liver, and kidney when using the
high TRIAC dose, TRIAC actions are achieved with no change
in T3 concentrations. Interestingly TRIAC is produced in WAT
of T3-treated rats and under cold exposure, an effect not
observed in any other tissue, raising the possibility that TRIAC
may have a role in regulating lipids and thermogenesis (leptin,
UCP-1, or LPL expression) in WAT. The lower tissue-to-
plasma ratios indicate that TRIAC does not enter as easily as
T3 into the tissues, especially under TRIAC infusion that
decreases tissue-to-plasma ratios in most tissues, except in
liver and kidney.
Our results disclose differences in the regulation of gene
expression when using T3 and TRIAC. The lower dose of
TRIAC was more effective than T3 in the upregulation of
UCP-1 mRNA, whereas no effect was seen at the high dose.
We show for the first time the induction of UCP-1 in BAT
in vivo at very low TRIAC concentrations, as previously
observed in cultured brown adipocytes (34). In the present
model, UCP-1 induction occurs without exogenous adrenergic
Fig. 7. Plasma leptin and leptin mRNA expression in WAT.
Plasma leptin (n  4–5 rats/group), WAT leptin mRNA,
rRNA staining, and leptin/rRNA ratio are shown (n  2;
means  SE). *P  0.05 vs. C.
Fig. 8. Type I and II Deiodinase (D1 and D2) activities
in liver, kidney, heart, BAT, pituitary, and brain. D1
activities in liver, kidney, and heart and D2 activities in
BAT, pituitary, and brain (pmol  min1  mg protein1
for D1 in liver and kidney and fmol h1 mg protein1 for
D1 in heart and D2 in BAT, pituitary, and cerebral cortex in
brain; n  5 / group; means  SE). *P  0.05 vs. C.
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stimulation (injection of NE). The lowest TRIAC dose was as
effective as the higher T3 dose in the induction of UCP-2 and
LPL in BAT, the inhibition of UCP-2 in muscle, and the
inhibition of LPL and leptin mRNA in WAT. It is possible that
TRIAC, acting through specific transcription factors, regulates
several genes through common pathways. The effect of the low
(but not high) doses of TRIAC was also observed in brown
adipocytes in culture (34), increasing the adrenergic stimula-
tion of UCP-1 and other genes such as D2, type III 5-deiodi-
nase, and LPL. Another compelling link between TRIAC and
thermogenesis was the induction of ectopic UCP-1 expression
in WAT, an effect not observed with any other treatment.
UCP-1 is considered a specific marker of BAT and thermo-
genic activity. Therefore, TRIAC was able to induce UCP-1 in
the so-called “convertible” WAT, meaning WAT that is con-
verted into BAT, by induction of UCP-1, as it happens under
intense cold exposure (28), 3-adrenergic stimulation, or leptin
treatment (11, 19, 45). Other experimental models have also
shown induction of UCP-1 in WAT, such as targeted disrup-
tion of the RII subunit of protein kinase A with decreased
WAT mass (12) and the targeted disruption of the corepressor
repressor interacting protein (RIP)140 (25). TRIAC at low
concentrations may induce the release of corepressors inducing
UCP-1, but this interaction remains to be demonstrated.
Several genes in liver and heart, with predominant TR-1
and -1 isoforms, respectively, were also studied to explore
whether the higher effect of TRIAC could be due to its higher
binding to the TR-1 isoform. Because the induction of hepatic
D1 was higher when using T3, it seems that the effects of
TRIAC at low doses do not depend on a higher abundance of
the TR-1 isoform, because it is not found in liver. Experi-
ments using hypothyroid mice treated with T3 or the specific
TR-1 ligand GC-1 showed that the stimulation of UCP-1 in
BAT is mediated by the TR-1 isoform, but GC-1 failed to
maintain core temperature under cold exposure, normalize
heart rate, or increase the adrenergic response (49). Thus the
higher effect of TRIAC observed here may be linked to a
specific action on specific coactivators or corepressors in adi-
pose tissue.
The study of the UCP family reveals that TRIAC regulates
UCP-2 expression differently in each tissue. UCP-2 expression
was increased in BAT and heart by T3 and TRIAC but was
decreased in muscle. The latter agrees with absent or minimal
stimulation of UCP-2 by T3 (24, 32), even after massive T3
doses. The stimulation of muscle UCP-2 is only found when T3
is given to thyroidectomized mice (21), but not in control mice.
UCP-3 expression was only upregulated by the highest dose of
T3. Therefore, the UCPs appeared to be regulated indepen-
dently.
To further study whether the actions of TRIAC at low doses
were preferentially found in adipose tissue, two additional
genes in adipose tissue (LPL and leptin) were examined.
Effects of the lowest TRIAC dose on LPL were observed in
BAT and WAT, although in opposite directions, but not in
heart. For leptin, the inhibition was observed using T3 and
TRIAC, in agreement with previous results in cultured brown
and white adipocytes (33), suggesting that LPL and leptin
could contribute to increased energy expenditure or lipid mo-
bilization in our model.
TRIAC (specially the low dose) had almost no effect in D1
activities, except in kidney. Indeed, the basal and T3-induced
expression of D1 is mostly dependent on TR-1, as shown
using TR-1- and TR-1-deficient mice (1), but whereas he-
patic D1 is dependent on TR-1 by 70%, and in a small
proportion on TR-1, in kidney there is no role for the TR-1
isoform. Kidney D1 is also less sensitive to T3 regulation. The
effect on D2 activity may be related to the decrease of T4 in the
tissues studied or to a stimulatory effect of T3 itself (15, 31).
The observed effects of T3 and TRIAC in heart do not give
a clear explanation for the different response, possibly due to
the action of T3 on other end points. The inhibition of -MHC
was similar for T3 and TRIAC, but little effect was found on
the other genes studied, despite the high TRIAC concentration
found in heart after TRIAC infusion (Fig. 3). Of note, T3
concentrations in heart were reduced by 50% under the highest
dose of TRIAC.
There were also many genes for which T3 had more effect
than TRIAC, such as the induction of D1 in liver, kidney, and
heart, D2 in BAT, pituitary, and brain, UCP-3 in BAT and
muscle, and LPL in heart. Conversely, some genes responded
similarly to T3 or TRIAC, for example UCP-2 and -MHC in
heart. The highest dose of T3 produces a larger effect, whereas
for TRIAC the larger effects are achieved using the smaller
doses.
In conclusion, whereas the effect of TRIAC at the pituitary
level has been well recognized, the effects on adipose tissue
Fig. 9. Expression of - and -myosin heavy chain (MHC)
and hyperpolarization-activated cyclic nucleotide-gated
channel 2 (HCN2) mRNAs in heart. Total RNA was ex-
tracted from heart of rats from experimental groups de-
scribed in Fig. 1. Hybridization with - and -MHC and
HCN2, rRNA staining, and ratios to RNAs are shown
(means  SE, n  4). *P  0.05 vs. C and #P  0.05 vs.
0.8 nmol T3.
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had not been analyzed in detail yet, except for the actions on
cholesterol and plasma lipids. Here we report the effect of low
doses of TRIAC in inducing UCP-1 mRNA and possibly
stimulating BAT and WAT thermogenesis. The ectopic expres-
sion of UCP-1 in WAT resembled other models in which there
is activation of thermogenesis and energy expenditure. The
effect of TRIAC at low doses on LPL or leptin reinforces its
role in activating energy metabolism. In addition, all these
effects are exerted without inhibition of TSH or hypothyrox-
inemia, contrary to the high doses of TRIAC. Thus, although
the administration of high doses of TRIAC should be avoided,
this study shows the physiological relevance of low doses of
TRIAC inducing thermogenic effects in adipose tissues, sug-
gesting that an increase in TRIAC production in adipose tissues
may be one mechanism to increase energy metabolism and
may be of benefit in the treatment of obesity.
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